Clinical Trial Update: Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, and pharmacodynamics of AUR112 in patients with relapsed advanced lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• AUR112

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Relapsed Advanced Lymphomas | Phase 1 | Status: RECRUITING